The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.